IRVING, Texas, Sept. 26 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced it has signed a Secrecy Agreement and Letter of Intent (LOI) with Sunstar Suisse, SA, a subsidiary of Sunstar, Inc., Osaka, Japan. Under the terms of the LOI, Carrington and Sunstar will investigate mutual business opportunities in international markets over the next two years.
"This is a great opportunity for us to partner with an innovative company that Carrington has worked and communicated with since 1994," stated Dr. Carlton Turner, President and CEO of Carrington. "Our core technologies in raw materials, drug delivery and final products capabilities, combined with Sunstar's global vision and market presence, is an ideal partnership. We look forward to this endeavor and are confident of mutually beneficial business opportunities in upcoming years."
The terms and conditions of the LOI are confidential and have not been disclosed at this time.
About Sunstar
Sunstar commenced business in 1941 and soon expanded its operations to include the health industry, beginning with the manufacturer and sale of toothpaste. It has since expanded its unique operations and core technologies. Today, Sunstar has emerged as a company that fosters health, beauty, safety and comfort through its products and services, in terms of both internal and external well-being. Sunstar's global organization includes corporate management operations in Switzerland as well as operating companies and offices in the four key hubs of Japan, Europe, North America and Asia. For more information, please visit http://www.sunstar.com .
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed August 14, 2006.
Carrington Laboratories, Inc.CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300
